Optimization of an Intranasal Route for the Delivery of Human Neural Stem Cells to Treat a Neonatal Hypoxic-Ischemic Brain Injury Rat Model
Siliang Lu,Ke Li,Yinxiang Yang,Qian Wang,Yu Yu,Zhaoyan Wang,Zuo Luan
DOI: https://doi.org/10.2147/NDT.S350586
IF: 2.989
2022-02-23
Neuropsychiatric Disease and Treatment
Abstract:Siliang Lu, 1, 2 Ke Li, 1, 2 Yinxiang Yang, 2 Qian Wang, 2 Yu Yu, 1, 2 Zhaoyan Wang, 2 Zuo Luan 1 1 The First Clinical Medical College, Guangxi Medical University, Nanning, 530021, Guangxi, People's Republic of China; 2 Laboratory of Pediatrics, The Sixth Medical Center of PLA General Hospital, Beijing, 100048, People's Republic of China Correspondence: Zhaoyan Wang, Laboratory of Pediatrics, The Sixth Medical Center of PLA General Hospital, Beijing, 100048, People's Republic of China, Tel +86-13581827961, Email Zuo Luan, The First Clinical Medical College, Guangxi Medical University, Nanning, Guangxi, 530021, People's Republic of China, Tel +86-18600310270, Fax +86-1066958303, Email Objective: Stem cell administration via the intranasal route has shown promise as a new therapy for hypoxic-ischemic encephalopathy (HIE). In this study, we aimed to improve the intranasal delivery of stem cells to the brain. Methods: Human neural stem cells (hNSCs) were identified using immunofluorescence, morphological, and flow cytometry assays before transplantation, and cell migration capacity was examined using the transwell assay. Cerebral hypoxia-ischemia (HI) was induced in 7-day-old rats, followed by the intranasal transplantation of CM-Dil-labeled hNSCs. We examined various experimental conditions, including preconditioning hNSCs with hypoxia, catheter method, multiple low-dose transplantation, head position, cell appropriate concentration, and volume. Rats were sacrificed 1 or 3 days after the final intranasal administration, and parts of the nasal tissue and whole brain sections were analyzed under a fluorescence microscope. Results: The isolated hNSCs met the characteristics of neural stem cells. Hypoxia (5% O 2 , 24 h) enhanced the surface expression of CXC chemokine receptor 4 (CXCR4) (9.21 ± 1.9% ∼ 24.76 ± 2.24%, P < 0.01) on hNSCs and improved migration (toward stromal cell-derived factor 1 [SDF-1], 0.54 ± 0.11% ∼ 8.65 ± 1.76%, P < 0.001; toward fetal bovine serum, 8.36 ± 0.81% ∼ 21.74 ± 0.85%, P < 0.0001). Further improvement increased the number of surviving cell distribution with increased uniformity on the olfactory epithelium and allowed the cells to stay in the nasal cavity for at least 72 h, but they did not survive for longer than 48 h. Optimization of pre-transplantation conditions augmented the success rate of intranasally delivered cells to the brain (0– 41.6%). We also tentatively identified that hNSCs crossed the olfactory epithelium into the tissue space below the lamina propria, with cerebrospinal fluid entering the cribriform plate into the subarachnoid space, and then migrated toward injured areas along the brain blood vessels. Conclusion: This study offers some helpful advice and reference for addressing the problem of repeatability in the intranasal delivery of stem cells. Keywords: neural stem cell, intranasal, optimization, transplantation, hypoxic-ischemic brain injury Hypoxic-ischemic encephalopathy (HIE) is a neonatal brain injury caused by reduced blood flow and oxygen supply to the neonatal brain and is one of the leading causes of death among infants. 1 As perinatal medicine continues to evolve, the rate of neonatal death has decreased significantly; however, the incidence of nervous system sequelae caused by HIE remains high, such as cerebral palsy, visual disturbance, and hearing loss. 2–4 Unfortunately, HIE treatment remains an unsolved clinical problem. Currently, therapeutic hypothermia is an important treatment option available for HIE, but it is only partially protective. 5 Since treatment strategies are limited for neonates with HIE, developing new, secure, and potent therapies to improve prognosis has great significance. Some preclinical and clinical studies have demonstrated the potential of stem cells for the treatment of HIE. 6–9 Stem cells self-renew throughout life and have the capacity for multipotent differentiation, and are thought to exert their beneficial effects through replacement and paracrine mechanisms when transplanted directly into the injured brain. 10 This implies that stem cell therapies are promising for the treatment of these devastating neonatal disorders. Stem cells can be delivered into the brain via different routes, and determining the optimal route of stem cell administration is a key problem that needs to be solved in stem cell therapy. 11 In the past decade, the intranasal pathway has been discovered as a new approach for delivering stem cells to the brain. 12 Advantages are that it is non-invasive, and it allows repetitive administration and cell targeting t -Abstract Truncated-
psychiatry,clinical neurology